NextCure Inc
Company Profile
Business description
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer’s disease.
Contact
9000 Virginia Manor Road
Suite 200
BeltsvilleMD20705
USAT: +1 240 399-4900
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
43
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,462.60 | 40.90 | 0.49% |
| CAC 40 | 7,743.75 | 49.31 | 0.64% |
| DAX 40 | 23,499.32 | 146.63 | 0.63% |
| Dow JONES (US) | 41,249.38 | 119.07 | -0.29% |
| FTSE 100 | 8,554.80 | 23.19 | 0.27% |
| HKSE | 22,867.74 | 91.82 | 0.40% |
| NASDAQ | 17,928.92 | 0.78 | 0.00% |
| Nikkei 225 | 37,503.33 | 574.70 | 1.56% |
| NZX 50 Index | 12,605.07 | 138.04 | 1.11% |
| S&P 500 | 5,659.91 | 4.03 | -0.07% |
| S&P/ASX 200 | 8,231.20 | 39.50 | 0.48% |
| SSE Composite Index | 3,342.00 | 10.00 | -0.30% |